Debates rekindled on government's stern measures on generic data fabrication

The controversy over the bioequivalence data fabrication has flared again following the government's unilateral administrative measure to cancel the licenses of generic drugs without lawful procedures.

In a statement delivered to the National Assembly, the Korea Pharmaceutical Manufacturers Association (KPMA) has called on the Korea Food and Drug Administration to consider withdrawing its ad...